Talasaz AmirAli 4
4 · Guardant Health, Inc. · Filed Jun 30, 2026
Research Summary
AI-generated summary of this filing
Guardant Health (GH) CEO AmirAli Talasaz Sells Shares, Exercises Options
What Happened
- AmirAli Talasaz, CEO of Guardant Health (GH), exercised stock options and sold common shares in open-market transactions. He exercised 254,832 shares at $4.18 per share (total exercise cost ≈ $1,065,198) and sold a total of 260,000 shares in multiple trades for aggregate proceeds of about $39,312,654. Net cash proceeds after exercise cost were roughly $38.25M.
- The transactions occurred on June 26 and June 29, 2026. The filing (Form 4) was submitted on June 30, 2026 and appears timely.
Key Details
- Transaction dates: 2026-06-26 and 2026-06-29.
- Exercise details: 111,804 shares (6/26) and 143,028 shares (6/29) exercised at $4.18 per share; exercise cost ≈ $1,065,198 total. Two additional derivative conversion lines at $0 reflect internal conversion reporting of the exercised instruments.
- Sales details: Six open-market sale line items totaling 260,000 shares at weighted-average prices in ranges noted in footnotes (overall proceeds ≈ $39,312,654). Footnotes F1–F4 give per-trade price ranges and note weighted-average reporting; detailed per-price breakdown is available on request.
- Vesting: Footnote F5 notes the underlying stock option vested in equal monthly installments over 48 months starting April 23, 2017 (i.e., the award has been vesting since 2017).
- Shares owned after transactions: Not specified in the provided excerpt of the filing.
- Timeliness: Filing dated 2026-06-30 for trades on 6/26 and 6/29; appears to meet Form 4 reporting timelines (not marked late).
Context
- These transactions appear to be an exercise of vested options followed by open-market sales (commonly a cashless exercise or immediate sell to cover exercise/tax obligations). Derivative reporting at $0 simply reflects conversion/reporting of the derivative instrument and is standard in Form 4s.
- Sales by executives can be routine (liquidity/tax planning) and do not by themselves indicate company performance; purchases generally carry more weight as a signal of insider confidence. This summary is factual and does not infer motivation.
Insider Transaction Report
Form 4
Talasaz AmirAli
DirectorCo-Chief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2026-06-26$4.18/sh+111,804$467,341→ 1,998,308 total(indirect: By Trust) - Sale
Common Stock
[F1]2026-06-26$150.49/sh−64,037$9,636,838→ 1,934,271 total(indirect: By Trust) - Sale
Common Stock
[F2]2026-06-26$151.16/sh−52,935$8,001,628→ 1,881,336 total(indirect: By Trust) - Exercise/Conversion
Common Stock
2026-06-29$4.18/sh+143,028$597,857→ 2,024,364 total(indirect: By Trust) - Sale
Common Stock
[F1]2026-06-29$150.53/sh−25,812$3,885,434→ 1,998,552 total(indirect: By Trust) - Sale
Common Stock
[F3]2026-06-29$151.47/sh−70,513$10,680,315→ 1,928,039 total(indirect: By Trust) - Sale
Common Stock
[F4]2026-06-29$152.20/sh−46,663$7,102,319→ 1,881,376 total(indirect: By Trust) - Sale
Common Stock
2026-06-29$153.00/sh−40$6,120→ 1,881,336 total(indirect: By Trust) - Exercise/Conversion
Stock Option (Right to Buy)
[F5]2026-06-26−111,804→ 172,025 totalExercise: $4.18Exp: 2027-07-14→ Common Stock (111,804 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F5]2026-06-29−143,028→ 28,997 totalExercise: $4.18Exp: 2027-07-14→ Common Stock (143,028 underlying)
Footnotes (5)
- [F1]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.99. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.79. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.99. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $152.00 to $152.68. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The stock option vested in equal monthly installments over 48 months commencing on April 23, 2017.
Signature
/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz|2026-06-30